Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cancer
- Disease
- cardiac
- Therapeutic
- Pharmaceuticals
- Autoimmune
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 282838
License Grant
Licensor hereby grants to Licensee and its Affiliates an exclusive license, with the right to sublicense, under the Licensor Technology to make, have made, use, sell, offer for sale, import, and export Products in the Field in the Territory.
License Property
Licensor has developed and owns or controls certain intellectual property rights with respect to a controlled release formulation of anagrelide.
Licensor Patents mean
US patent 6,585,995 Methods and compositions for treating platelet-related disorders
US Patent Application 20130022671
Field of Use
GALE-401 contains the active ingredient anagrelide, an FDA-approved product, which has been in use since the late 1990s for the treatment of essential thrombocythemia (ET).
Essential thrombocythemia (ET) is a rare chronic blood cancer (myeloproliferative neoplasm) characterised by the overproduction of platelets (thrombocytes) by megakaryocytes in the bone marrow.
Cardiovascular Field means the direct prevention, treatment, diagnosis of myocardial infarction, strokes and peripheral arterial disease in humans or other animals. For sake of clarity the Cardiovascular Field will not include the prevention, treatment or diagnosis of conditions that may ultimately lead to a decrease in the risk of thrombotic events, such as Myeloproliferative Disorders and other hematological indications.
IPSCIO Record ID: 204382
License Grant
The Licensor and the Licensee wish to resolve the dispute regarding Licensees Commercially Reasonable Efforts to Develop the controlled release formulation of anagrelide by making certain amendments to the License Agreement. Anagrelide is a treatment for thrombocythemia – the overproduction of blood platelets.
License Property
Essential thrombocythemia (ET) is a rare chronic blood condition characterised by the overproduction of platelets by megakaryocytes in the bone marrow. Essential thrombocythemia (ET) is one of a related group of blood cancers known as “myeloproliferative neoplasms†(MPNs) in which cells in the bone marrow that produce the blood cells develop and function abnormally. … ET does not generally shorten life expectancy.
The Licensor is a biotechnology company, developing and commercializing drugs and devices for the control of hyperplasia associated with vascular procedures and control of cardiovascular risk factors.
Field of Use
The Licensee designs and develops active ingredient anagrelide, GALE-401 (Anagrelide CR) used for treatment of Essential Thrombocythemia.
IPSCIO Record ID: 4475
License Grant
The license agreement has the Primary Licensor granting an exclusive worldwide license to the Primary Licensee. Royalties associated with this license are marked confidential and not available other than a stated range. In the termination clause, royalty rate information is available for the cross license. The Primary Licensee is now the Licensor and shall be deemed without any further action to have granted to Licensee (was Primary Licensor) a non-exclusive, worldwide, royalty-bearing license (including the right to grant sublicenses), under the know-how and patents controlled by Licensor (formerly Licensee) on the effective date of termination solely covering inventions (1) conceived and reduced to practice by Licensor (formerly Licensee) solely in connection with the Development of the Product and (2) necessary to make, use and sell Product, for use by Licensee as reasonably necessary to develop, have developed, make, have made, use, have used, offer for sale, sell, have sold, import and have imported the Products. This grant clause becomes effective if the original license is terminated and the clause is a commitment that the Primary Licensor (now Licensee) pay royalties to the Primary Licensee (now Licensor).
License Property
Licensee (formerly Licensor) has developed and owns or controls certain intellectual property rights with respect to a controlled release formulation of anagrelide, among other things, and owns or controls certain know-how, technology, documentation, data, and other materials relating thereto.
The license cites the following as relevant US patent 6,585,995 B1; US Patent Application 20130022671; Issued UK Patent GB 2462022B; Issued UK Patent GB 2460915B; PCT/US2009/003632 (Publication No. WO 2010/005480)
US patent 6,585,995 B1
US Patent Application 20130022671
Issued UK Patent GB 2462022B
Issued UK Patent GB 2460915B
PCT/US2009/003632 (Publication No. WO 2010/005480) and related regional and national applications
Field of Use
The Cardiovascular Field means the direct prevention, treatment, diagnosis of myocardial infarction, strokes and peripheral arterial disease in humans or other animals. For sake of clarity the Cardiovascular Field will not include the prevention, treatment or diagnosis of conditions that may ultimately lead to a decrease in the risk of thrombotic events, such as Myeloproliferative Disorders and other hematological indications.
Myeloproliferative disorders is the name for a group of conditions that cause blood cells, platelets, white blood cells, and red blood cells, to grow abnormally in the bone marrow.
IPSCIO Record ID: 203285
License Grant
Licensor grants an exclusive, worldwide, non-transferable, license, with the right to sublicense, under the Licensor Patent Rights and Know-How to make, use, including in activities directed at the research and Development of Licensed Compounds, have made, sell, have sold, offer to sell, export, import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.
Licensor grants a non-transferable, non-exclusive license, with the right to sublicense, under the Licensor Other Patent Rights solely to the extent reasonably necessary to make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, offer to sell, export and import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.
License Property
MS564929 Toxicology Studies means the two (2) toxicology reports due n the IND covering the BMS compound designated BMS564929, specifically the 6 onth oral toxicology studies in rats and dogs.
6,670,386 – Bicyclic modulators of androgen receptor function
The licensed compounds and patents relate to controlling various diseases and cancers.
Field of Use
The Field means the diagnosis, prevention, treatment or control of any human or animal disease, disorder or condition, excluding the prevention, treatment or control of any human or animal hyperproliferative disease, disorder or condition. For purposes of clarity, hyperproliferative diseases, disorders and conditions are those diseases, disorders or conditions which are characterized by an abnormal increase in the proliferation or accumulation of cells and include conditions such as cancers and benign hyperplasia, but not diseases, disorders or conditions incident to an abnormal increase in the proliferation or accumulation of cells.
IPSCIO Record ID: 269086
License Grant
This exclusive license agreement with Licensee is to commercialize fostamatinib in all indications, including chronic ITP, AIHA, and IgAN, in Europe and Turkey. Licensee will receive exclusive rights to fostamatinib in human diseases, including chronic immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and IgA nephropathy (IgAN).
License Property
Fostamatinib refers to fostamatinib disodium hexahydrate which is an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment (product called TAVALISSE®)
The Licensor is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The pioneering research focuses on signaling pathways that are critical to disease mechanisms.
Field of Use
Fostamatinib is a medication for the treatment of chronic immune thrombocytopenia.
Adult chronic immune thrombocytopenic purpura (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes (the cells that produce platelets in the bone marrow), causing a decrease in platelet production. This results in a low blood platelet count (thrombocytopenia) that may produce bruising or excessive bleeding.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
